In a filing, Mirum Pharmaceuticals Inc revealed its CHIEF FINANCIAL OFFICER BJERKHOLT ERIC acquired Company’s shares for reported $49600.0 on Mar 27 ’24. In the deal valued at $24.80 per share,2,000 shares were bought. As a result of this transaction, BJERKHOLT ERIC now holds 14,000 shares worth roughly $0.36 million.
Then, Radovich Peter sold 4,303 shares, generating $111,017 in total proceeds. Upon selling the shares at $25.80, the PRESIDENT AND COO now owns 29,013 shares.
Before that, BJERKHOLT ERIC bought 2,000 shares. Mirum Pharmaceuticals Inc shares valued at $51,600 were divested by the CHIEF FINANCIAL OFFICER at a price of $25.80 per share. As a result of the transaction, BJERKHOLT ERIC now holds 12,000 shares, worth roughly $0.31 million.
Stifel initiated its Mirum Pharmaceuticals Inc [MIRM] rating to a Buy in a research note published on April 17, 2024; the price target was $48. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who remained covering the stock and in mid December has reiterated a ‘”a Buy”‘ rating for it. Morgan Stanley started covering the stock on November 13, 2023. It rated MIRM as “an Overweight”.
Price Performance Review of MIRM
On Tuesday, Mirum Pharmaceuticals Inc [NASDAQ:MIRM] saw its stock fall -1.82% to $25.91. Over the last five days, the stock has gained 3.19%. Mirum Pharmaceuticals Inc shares have fallen nearly -12.23% since the year began. Nevertheless, the stocks have fallen -1.22% over the past one year. While a 52-week high of $35.56 was reached on 01/03/24, a 52-week low of $23.14 was recorded on 04/25/24. SMA at 50 days reached $26.08, while 200 days put it at $28.07. A total of 0.27 million shares were traded, compared to the trading of 0.34 million shares in the previous session.
Levels Of Support And Resistance For MIRM Stock
The 24-hour chart illustrates a support level at 25.41, which if violated will result in even more drops to 24.91. On the upside, there is a resistance level at 26.59. A further resistance level may holdings at 27.27. The Relative Strength Index (RSI) on the 14-day chart is 55.35, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.15, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 23.69%. Stochastics %K at 86.17% indicates the stock is a selling.
The most recent change occurred on October 24, 2023 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating along with a $50 price target.
